The OutSmarting Osteosarcoma 2024 research grant application is now closed. Our 2025 grant cycle will open in Q4 2024.
The OutSmarting Osteosarcoma Research Award
$100,000 grant over one year to select investigators with a compelling study that will Make It Better for osteosarcoma patients.
The OutSmarting Osteosarcoma Young Investigator (YI) Research Award
$50,000 grant over one year to select young investigators with a compelling study that will Make It Better for osteosarcoma patients.
Awards may be sponsored by one MIB Agents Family Fund or individual donor, which is co-branded in honor of the Family Fund. The number of grants by award type will be determined based on budget and program goals during programmatic review.
$1,550,000 awarded to date
The OutSmarting Osteosarcoma Research Grant is an annual award begun in 2017. Since then, MIB Agents has supported eighteen investigators and awarded $1,550,000 to support osteosarcoma research.
Family Funds Supporting Science
Collaboration among the scientific and patient community is a key hallmark of MIB Agents. MIB Agents OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients and families who raise funds in honor of an OsteoWarrior or OsteoAngel. Their dedication to Making It Better and fostering collaboration and education in the scientific community makes every MIB Agents award incredibly meaningful.
Our collaborative and robust review process
The two tier-review process results in a robust and collaborative review process that uniquely
incorporates patient and family perspective.
Please email firstname.lastname@example.org with any questions.
Since 2017, MIB Agents has funded 18 studies and $1,550,000 in osteosarcoma research. But the impact of this investment extends far beyond these studies. As of result of OutSmarting Osteosarcoma's investment, MIB Agents funded studies have resulted in:
78 Presentations sharing findings with the scientific community
10 Publications disseminating findings into the public domain
7 clinical trials opened
$11.5 million secured in additional osteosarcoma research funding